



Connecting Markets
Creating Opportunities

7 October 2026

Redox 2026 AGM Chair's Address and Presentation

Redox Limited (ACN 000 762 345) (ASX:RDX) (**Redox**) Annual General Meeting (**AGM**) Chair's Address and presentation to be delivered at today's AGM in Sydney is **attached**.

- ends -

This announcement is authorised for release by the Board of Redox Limited.

For enquiries, please contact:

Investor Relations
Howard Marks
Automic Markets
+61 402 438 019
howard.marks@automicgroup.com.au

About Redox

Established in 1965, Redox markets a range of more than 1,000 different chemicals, ingredients and raw materials, sourced from leading manufacturers supplied to clients throughout Australia, New Zealand, Malaysia and North America. Our dedicated team of more than 400 employees operate from 19 locations across the globe, with more than 100 convenient storage locations. A growing business with sales revenue of over \$1.33 billion in the financial year 2026. Redox looks for long term partnerships, where shared values and common goals align for mutual benefit. Our relationships are open, innovative and based on teamwork.

<https://redox.com>



7 October 2026

Redox Limited 2026 Annual General Meeting Chair's Address

It has been another strong year for Redox, with the Company achieving record revenue and strong profitability despite the subdued operating environment.

Sales revenue growth was primarily organic and volume based as higher replacement prices only started to be felt during Q4.

Gross Profit margins increased as product mix improved and we were rewarded for helping clients navigate more volatile market conditions.

As a result, I am pleased to say we delivered a 20% increase in earnings per share.

For FY26, the Board declared total dividends of 13 cents per share, 4% higher than FY25. This represents 74% of net profit after tax and is comfortably within our stated payout policy of 60% to 80%.

While our business continues to deliver consistent returns, we recognise future growth will not come from business as usual alone. Although no acquisitions were completed during FY26, I can assure shareholders our domestic and international opportunity pipeline remains very much alive.

This includes an increased focus on the strategically important North American market, where we aim to build on revenue of just over \$100 million. With cash and cash equivalents of \$123 million, zero net debt and a conservatively geared balance sheet, Redox is well positioned to fund the right acquisitions comfortably.

Technology continues to underpin our operations, bringing both opportunities and rapidly evolving risks. Our internally developed Redebiz system is central to the way we manage and control many aspects of the business. In particular, it supports commercial and marketing strategies that have been refined through many years of experience and expertise.

We protect these systems and the valuable information they contain through a disciplined approach to cyber and information security, supported by rigorous and ongoing testing.

During the year, we benchmarked Board and Executive remuneration and incentive arrangements to ensure they remain appropriately aligned with the market and shareholder interests. FY27 performance rights for Executives now contain two equally weighted performance hurdles: total shareholder return relative to a comparator group and growth in earnings per share.

Board succession has also been an important focus. We announced my retirement, with Mary Verschuer to succeed me as Chair following the AGM, together with the appointment of Sheila Lines as an Independent Non-Executive Director. The Board remains strongly committed to diversity and to maintaining Redox's reputation as a great place to work.

In FY27, our focus will remain on delivering revenue growth—both organically and through acquisitions—while carefully managing operational and logistics costs in a volatile, uncertain and inflationary environment. We will also continue to optimise inventory and embrace the benefits of artificial intelligence where it can add genuine value to our business.

I have enjoyed my time with Redox and have been fortunate to witness a long-standing family company transition successfully to the public market while continuing to deliver consistently strong results.

It has been a privilege to serve the Company and to work alongside such a talented Board, an accomplished management team and a dedicated group of employees. I thank them all for their support and contribution.

I will now ask Raimond Coneliano to provide an overview of the Company's performance during FY26.

Ian Campbell,
Chair

-END-



CONNECTING MARKETS
CREATING OPPORTUNITIES

FY26

AGM Presentation

7th October 2026

REDOX LIMITED (RDX.ASX)



Agenda

1. Chair's Introduction
2. CEO's Presentation
3. Q&A
4. Formal Business Of Meeting



Chair's Introduction

Ian Campbell
Chair






CEO's Presentation

Raimond Coneliano

Chief Executive Officer & Managing Director



FY26 Highlights

REDOR

\$1.330b

Sales Revenue
+6.9% growth vs PCP

14.6%

After Tax ROIC
+1.1ppts vs PCP

\$298m

Gross Profit
+11.0% vs PCP

22.4%

Gross Profit Margin
+0.8ppts vs PCP

\$92m

Net Profit After Tax
+19.2% vs PCP

\$134m

EBITDAFX
+9.9% vs PCP

44.8%

Conversion Margin
(Gross Profit to EBITDAFX)

6.5 cps

Final Dividend
Payout ratio 74%

Dividend

Final Dividend for FY26 of 6.5 cents per share

Full Year Dividend of 13 cents per share (up 4% on PCP) represents a pay out of 74% of profits

Final Dividend paid on the 22 September 2026


Record date 26 August 2026

Long term Dividend payout ratio will be 60%-80% of profits



FY26 sales increased by 6.9% vs PCP to a new high of \$1.330b driven primarily by organic growth, supplemented by acquired business against the backdrop of subdued demand

- North American Sales grew 33.8% to over \$100m for the first time
- Acquired business Molekulis successfully integrated onto Redebiz contributing to APAC’s healthy sales revenue growth
- Product availability, Replacement Price and demand impacted by the Middle-East Conflict and macroeconomic flow-on effects
- Selling Prices were relatively flat FY26 vs PCP, however increased half over half
- Gross Margin rose to 22.4% due to product mix improvement in APAC and improving margin profile in North America




Company Data, graph is approximate to the nearest million dollars AUD

Australian sales grew 6.1% to \$1.120b

- Through its acquisition of Molekulis*, Redox now have sales of Transformer Oil to Transformer manufacturers, energy generators and transmission businesses
- Major growing segments in APAC - Industrial, Crop Production & Protection, Food, Animal Health & Nutrition
- NZ result impacted by drop in demand from Human Health industry segment

North American sales increased 33.8% exceeding \$100m

- Customer conversions and share of wallet wins across the Industrial, Food, Human Health and Personal Care segments
- 47 new Active Products added to portfolio
- Growing sales in recently established US Southeast region, first success in Canadian market



* Completion of Redox's acquisition of Molekulis Pty Ltd and Molekulis Limited ("Molekulis") 30th of April 2025




8,700+
ACTIVE CUSTOMERS



5,500+
SKU'S



100+
STOCK LOCATIONS



1,200+
ACTIVE SUPPLIERS




494
STRONG TEAM



1,200+
PRODUCT GROUPS

Primary focus organic growth complimented by acquisitions & geographic expansion

30-year revenue CAGR of 10.1%



Extensive and growing customer, supplier and product base

Globally significant chemical distributor

Trained the Redox way – certified Great Place To Work

Q1 FY27 Update

- Average Selling Prices were approximately 9% higher than PCP
- Volumes sold were broadly in line with PCP
- Inwards Sea Freight and Outbound Freight Costs continue to rise due to inflationary forces e.g. fuel costs
- Gross profit margins remained resilient and above FY26



Q&A

Raimond Coneliano

Chief Executive Officer & Managing Director






Formal Business Of Meeting



How to vote

- When the poll is open, select the vote icon at the top of the screen
- To vote, select either For, Against or Abstain
- You will see a vote confirmation
- To change or cancel your vote “click here to change your vote” at any time until the poll is closed



Broadcast **Vote** Q & A Documents

Items of Business

2A Re-elect Mr Sam Sample as a Director


FOR AGAINST ABSTAIN

2B Re-elect Ms Jane Citizen as a Director


We have received your vote **For**
[Click here to change your vote.](#)

How to ask a question

- To ask a written question select the Q&A icon
- Select the topic your question relates to from the drop-down list
- Type your question in the text box and press the send icon 
- To ask a verbal question follow the instructions below the broadcast window



The screenshot shows the REDOX user interface for asking a question. At the top, there are four navigation icons: a monitor for 'Broadcast', a document with a '1' for 'Vote', a speech bubble for 'Q & A' (which is highlighted with a purple underline), and a folder for 'Documents'. Below the navigation bar, the text 'Select a topic and type your question.' is displayed. A dropdown menu shows '3. Adoption of Remuneration Report' with a downward arrow. Below the dropdown is a large text input area with the placeholder text 'Enter your question here'. To the right of the text box is a purple square button with a white curved arrow pointing right. At the bottom left of the input area, it says '24 out of 2000 characters.'



Items of Business

Item 1 – Financial Report

Item 2 – Adoption of Remuneration Report

Item 3 – Re-Election and Election of Directors

Item 3.1 – Renato Coneliano

Item 3.2 – Garry Wayling

Item 3.3 – Sheila Lines

Item 4 – Grant of Performance Rights

Item 4.1 – Raimond Coneliano

Item 4.2 – Renato Coneliano

Item 4.3 – Richard Coneliano

Proxy Votes

Item 2 – Adoption of the Remuneration Report

For	Against	Open	Abstain	Excluded
113,111,861	1,652,687	212,623	131,958	63,215,409
98.38%	1.44%	0.18%	N/A%	N/A%

Proxy Votes

Item 3 – Re-Election and Election of Directors

Item 3.1 Re-Election of Renato Coneliano, Marketing Director

For	Against	Open	Abstain	Excluded
167,884,610	7,206,376	212,623	33,158	0
95.77%	4.11%	0.12%	N/A%	N/A%

Item 3.2 Re-Election of Garry Wayling, Independent Non-Executive Director

For	Against	Open	Abstain	Excluded
176,049,717	1,982,010	246,623	46,188	0
98.76%	1.11%	0.13%	N/A%	N/A%

Item 3.3 Election of Sheila Lines, Independent Non-Executive Director

For	Against	Open	Abstain	Excluded
168,128,913	9,904,659	212,623	78,343	0
94.33%	5.56%	0.11%	N/A%	N/A%

Proxy Votes

Item 4 – Grant Of Performance Rights to Executive Directors

Item 4.1 Raimond Coneliano, CEO & Managing Director

For	Against	Open	Abstain	Excluded
113,826,255	1,027,199	212,623	86,958	63,171,503
98.93%	0.89%	0.18%	N/A%	N/A%

Item 4.2 Renato Coneliano, Marketing Director (Executive Director)

For	Against	Open	Abstain	Excluded
113,826,255	1,027,199	212,623	86,958	63,171,503
98.93%	0.89%	0.18%	N/A%	%

Item 4.3 Richard Coneliano, Chief Operating Officer (Alternate Director)

For	Against	Open	Abstain	Excluded
113,826,255	1,025,114	214,708	86,958	63,171,503
98.93%	0.89%	0.18%	N/A%	N/A%

REDOX

Voting Complete

Important notices

This Presentation has been prepared by Redox Limited (ABN 92 000 762 345) (“RDX” or “Company”).

Summary information

This Presentation contains summary information about RDX and its activities current as at 30 June 2026. The information in the Presentation is of a general nature and does not purport to be complete or comprise all information which a shareholder or potential investor may require in order to determine whether to deal in RDX shares. It should be read in conjunction with RDX’s other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange, which are available at www.asx.com.au.

Not financial product advice

This Presentation is for information purposes only and is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law (and will not be lodged with the Australian Securities and Investments Commission) or under any other law. This Presentation does not constitute financial product, investment, legal, taxation or other advice or a recommendation to acquire RDX shares and has been prepared without considering the objectives, financial situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and seek financial, legal and taxation advice appropriate to their jurisdiction. The Company is not licensed to provide financial product advice in respect of its shares. Cooling off rights do not apply to the acquisition of RDX shares.

Financial data

All dollar values are in Australian dollars (\$) unless stated otherwise.

Non-IFRS Financial information

RDX's results are reported under International Financial Reporting Standards (IFRS). This presentation also includes certain non-IFRS measures including "underlying", "adjusted" and "pro-forma" and other measures that are used internally by management to assess the operational performance and management of the Group. Non-IFRS measures have not been subject to audit or review. All numbers listed as “statutory” comply with IFRS and have been audited.

Past performance

Past performance information given in this Presentation is given for illustrative purposes only and should not be relied upon as an indication of future performance.

Future performance

This presentation contains certain “forward-looking statements” including statements regarding our intent, belief or current expectations with respect to the Company’s business and operations, market conditions, results of operations and financial condition, and risk management practices. The words “likely”, “expect”, “aim”, “should”, “could”, “may”, “anticipate”, “predict”, “believe”, “plan” and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. This Presentation contains such statements that are subject to risk factors associated with an investment in RDX. RDX believes that the expectations reflected in these statements are reasonable, but they may be affected by a range of variables which could cause actual results or trends to differ materially.

REDOX



RedoxGlobal



Redox Limited



Redox_global